fibrinogen-binding peptide

Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen, a soluble plasma protein, serves as a cofactor in platelet activation and is converted.

Fibrinogen-Binding Peptide 137235-80-4(fb-acetate) 是纤维蛋白原受体上玻连蛋白结合位点的推定肽模拟物。它结合纤维蛋白原并抑制血小板与纤维蛋白原的粘附和血小板聚集，还抑制血小板与玻连蛋白的粘附

Arg-Gly-Glu-Ser acetate(93674-97-6 free base) 是一种 RGD 相关肽，可控制纤维蛋白原与活化血小板结合的 RGDS 活性。

Angstrom6 (A-6 peptide) 是一种从单链尿激酶纤溶酶原激活剂(scuPA)中提取的 8 肽，它能干扰 uPA uPAR 级联反应并抑制下游效应。Angstrom6 具有抗肿瘤活性，能通过与 CD44 结合并调节 CD44 介导的细胞信号传导，抑制肿瘤细胞的迁移、侵袭和转移。

Arg-Gly-Glu-Ser TFA，作为RGD相关多肽，调节RGDS对纤维蛋白原及活化血小板结合的抑制作用。

K-Casein (106-116), bovine，为一抗血小板聚集与纤维蛋白原结合的多肽，动脉粥样硬化关键作用因子。

Arg-Gly-Glu-Ser (RGDS) is an RGD-related peptide used as a control for the activity of fibrinogen binding to activated platelets.

Fibrinogen Binding Inhibitor Peptide, a synthetic dodecapeptide, represents the specific platelet receptor recognition site of the human fibrinogen g-chain (residues 400-411).